back
The following table presents a selection of major awards and rankings for 2013 and 2014. Information on additional rankings and awards received by individual businesses or sites can be found in the respective chapter of the 2014 Corporate Responsibility Report, or on our company's website.
Recognition and rankings for 2013 and 2014 |
|
|
|
|
|
Name |
For? |
The Carbon Disclosure Project (CDP) is a not-for-profit organization that, on behalf of investors, purchasers and governments, has pioneered a disclosure system enabling companies to transparently report their greenhouse gas emissions and water use. In the Carbon Disclosure Leadership Index, which assesses the level of reporting detail as well as transparency, Merck scored 87 out of 100 possible points. In the Carbon Disclosure Performance Index, which measures corporate performance in reducing emissions, Merck was graded B on a scale of E to A, which clearly places us in the upper performance band among all companies from Germany, Austria and Switzerland. |
|
Since 2008, Merck has been included in the FTSE4Good Index, a leading international sustainability index that annually evaluates companies' social, environmental and ethical performance. |
|
In 2013, oekom research AG, a sustainability ratings agency, gave Merck a C+ on a scale of D- to A+ (top grade). Merck thus once more achieved Prime Status. |
|
In 2014, Merck's stocks were once again included in STOXX Global ESG Leaders, a sustainability index that assesses companies based on key environmental, social and governance criteria. |
|
Ethibel Sustainability Index (ESI) Excellence Europe and Ethibel EXCELLENCE Investment Register |
Merck has been selected as a constituent of the Ethibel Sustainability Index (ESI) Excellence Europe since 23/03/2015. The ESI indices universe is composed of companies included in the Russell Global Index that display the best performance in the field of Corporate Social Responsibility. |
In the Access to Medicine Index, Merck went from 8th place in 2012 to 6th in 2014. This Index assesses 20 pharmaceutical companies with respect to their activities to improve access to medicine in developing countries. The index is published every two years by the Access to Medicine Foundation, an international not-for-profit organization. |
|
